Betaxolol (tablet): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
Line 1: Line 1:
{{drugbox |
__NOTOC__
| image=betaxolol.png
| IUPAC_name =1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol
| CAS_number = 63659-18-7
| ATC_prefix=C07
| ATC_suffix=AB05
| ATC_supplemental={{ATC|S01|ED02}}
| PubChem=2369
| ChemSpiderID=2279
| DrugBank=APRD00245
| C=18 | H=29 | N=1 | O=3
|molecular_weight = 307.428 [[gram|g]]/[[Mole (unit)|mol]]
|smiles = CC(C)NCC(O)COc1ccc(cc1)CCOCC2CC2
|bioavailability = 89%
|metabolism = [[Liver|Hepatic]]
|elimination_half-life = 14–22 hours
|excretion = [[Kidney|Renal]] (20%)
|pregnancy_AU = C
|pregnancy_US = C
|pregnancy_category =
|legal_status = Rx-only
|routes_of_administration = oral, [[ocular]]
}}


{{SI}}
{{Betaxolol}}
{{CMG}}; {{AE}} {{SS}}


'''''For patient information about Betaxolol, click [[Betaxolol (patient information)|here]]'''''




'''Betaxolol''' (trade names '''Betoptic''', '''Betoptic S''', '''Lokren''', '''Kerlone''') is a selective [[beta blocker|beta<sub>1</sub> receptor blocker]] used in the treatment of [[hypertension]] and [[glaucoma]]. Being selective for beta<sub>1</sub> receptors, it typically has fewer systemic [[adverse drug reaction|side effect]]s than non-selective beta-blockers, for example, not causing [[bronchospasm]] (mediated by beta<sub>2</sub> receptors) as [[timolol]] may.  Betaxolol also shows greater affininty for beta<sub>1</sub> receptors than [[metoprolol]]. In addition to its effect on the heart, betaxolol reduces the pressure within the eye ([[intraocular pressure]]). This effect is thought to be caused by reducing the production of the liquid (which is called the [[aqueous humor]]) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the [[optic nerve]] and loss of vision in patients with elevated intraocular pressure due to [[glaucoma]].  
{{SB}} BETOPTIC<sup>®</sup>
 
==Overview==
'''Betaxolol''' (trade names '''Betoptic''', '''Betoptic S''', '''Lokren''', '''Kerlone''') is a selective [[beta blocker|beta<sub>1</sub> receptor blocker]] used in the treatment of [[hypertension]] and [[glaucoma]]. Being selective for beta<sub>1</sub> receptors, it typically has fewer systemic[[adverse drug reaction|side effect]]s than non-selective beta-blockers, for example, not causing [[bronchospasm]] (mediated by beta<sub>2</sub>receptors) as [[timolol]] may.  Betaxolol also shows greater affininty for beta<sub>1</sub> receptors than [[metoprolol]]. In addition to its effect on the heart, betaxolol reduces the pressure within the eye ([[intraocular pressure]]). This effect is thought to be caused by reducing the production of the liquid (which is called the [[aqueous humor]]) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the [[optic nerve]] and loss of vision in patients with elevated intraocular pressure due to [[glaucoma]].  


Betaxolol was approved by the U.S. [[Food and Drug Administration]] (FDA) for ocular use as a 0.5% solution ('''Betoptic''') in 1985 and as a 0.25% solution ('''Betoptic S''') in 1989.
Betaxolol was approved by the U.S. [[Food and Drug Administration]] (FDA) for ocular use as a 0.5% solution ('''Betoptic''') in 1985 and as a 0.25% solution ('''Betoptic S''') in 1989.
==Category==
Cardiovascular Drugs:Beta blockers
==FDA Package Insert==


==Clinical uses==
'''| [[Betaxolol indications and usage|Indications and Usage]]'''
* Oral: for the management of hypertension
'''| [[Betaxolol dosage and administration|Dosage and Administration]]'''
* Ophthalmic: for the management of glaucoma
'''| [[Betaxolol dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Betaxolol contraindications|Contraindications]]'''
'''| [[Betaxolol warnings and precautions|Warnings and Precautions]]'''
'''| [[Betaxolol adverse reactions|Adverse Reactions]]'''
'''| [[Betaxolol drug interactions|Drug Interactions]]'''
'''| [[Betaxolol use in specific populations|Use in Specific Populations]]'''
'''| [[Betaxolol overdosage|Overdosage]]'''
'''| [[Betaxolol description|Description]]'''
'''| [[Betaxolol clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Betaxolol nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Betaxolol clinical studies|Clinical Studies]]'''
'''| [[Betaxolol how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Betaxolol patient counseling information|Patient Counseling Information]]'''
'''| [[Betaxolol labels and packages|Labels and Packages]]'''


==Dosage==
==Mechanism of Action==
* Oral: The initial dose in hypertension is ordinarily 10 mg once daily either alone or added to diuretic therapy.
* Ophthalmic: The recommended dose is one to two drops in the affected eye(s) twice daily.


==Contraindications==
==References==
* Hypersensitivity to the drug
* Patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure


==External links==
{{Reflist|2}}
* [http://products.sanofi-aventis.us/kerlone/kerlone.pdf Kerlone prescribing information]


==See also==
[[Levobetaxolol]]
{{beta blockers}}
{{Antiglaucoma preparations and miotics}}


[[Category:Beta blockers]]
[[Category:Beta blockers]]
 
[[Category:Cardiovascular Drugs]]
[[it:Betaxololo]]
[[pl:Betaksolol]]
 
<small>'''''Synonyms / Brand Names:''''' </small>
 
{{FDA}}
 
[[Category:Drugs]]
[[Category:Drugs]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 20:55, 3 February 2014


Betaxolol
BETOPTIC® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Clinical Trials on Betaxolol
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Betaxolol, click here


Synonyms / Brand Names: BETOPTIC®

Overview

Betaxolol (trade names Betoptic, Betoptic S, Lokren, Kerlone) is a selective beta1 receptor blocker used in the treatment of hypertension and glaucoma. Being selective for beta1 receptors, it typically has fewer systemicside effects than non-selective beta-blockers, for example, not causing bronchospasm (mediated by beta2receptors) as timolol may. Betaxolol also shows greater affininty for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye (intraocular pressure). This effect is thought to be caused by reducing the production of the liquid (which is called the aqueous humor) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

Betaxolol was approved by the U.S. Food and Drug Administration (FDA) for ocular use as a 0.5% solution (Betoptic) in 1985 and as a 0.25% solution (Betoptic S) in 1989.

Category

Cardiovascular Drugs:Beta blockers

FDA Package Insert

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Betaxolol_(tablet)&oldid=937729"